Evidence map›Paper›PMID 34049893›Full record

ArticleBMJ case reports2021

Sclerosing cholangitis in a patient treated with nivolumab.

Sam Talbot, Vivienne MacLaren, Heather Lafferty

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Sam TalbotGastroenterology, NHS Greater Glasgow and Clyde, Glasgow, UK sam.talbot@ggc.scot.nhs.uk.ORCID http://orcid.org/0000-0002-6988-732X
Vivienne MacLarenClinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
Heather LaffertyGastroenterology, NHS Greater Glasgow and Clyde, Glasgow, UK.
NHS Greater Glasgow and Clyde · GBBeatson West of Scotland Cancer Centre · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 69-year-old retired miner with stage 4 non-small-cell lung cancer presented with a 2-month history of obstructive liver function tests following nivolumab immunotherapy. His case had not responded to high dose prednisolone or mycophenolate and he was admitted for investigation. MR cholangiopancreatography demonstrated areas of intrahepatic biliary tree beading and stricturing, in keeping with sclerosing cholangitis. Prednisolone and mycophenolate were stopped and ursodeoxycholic acid commenced with subsequent partial improvement of the patient's liver function tests.

Indexed as

Carcinoma, Non-Small-Cell LungCholangitis, SclerosingLung NeoplasmsAgedHumansMaleNivolumabUrsodeoxycholic AcidNivolumabUrsodeoxycholic Acidliver diseaselung cancer (oncology)radiologyunwanted effects / adverse reactions

Identifiers

PMID34049893
PMCPMC8166617
OpenAlexW3164636366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.